Zharp2-1
Based on 1 Customer Validation
Zharp2-1 is an oral effective RIPK2 inhibitor, highly associated with inflammatory bowel disease (IBD). Zharp2-1 blocker muramyl dipeptide (MDP) induces growth of mononuclear cells and induces inflammatory cell factor infection. Zharp2-1 attenuates MDP-induced small inguinal peritonitis, or ameliorates by DNBS-induced large inguinal conjunctivitis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.10%
- CAS No.: 2772600-18-5
- Formule: C19H18N3O2PS
- Masse moléculaire:383.40
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Activité biologique
RIPK2[1]
Zharp2-1 pretreats THP-1 and iBMDM cells for 2 h, and inhibits the release of IL-6 and TNF-α induced by 10 μg/mL MDP or 1 μg/mL L18-MDP for 12 h[1].
Zharp2-1 significantly inhibits MDP-induced cytokine release in PBMCs, with an IC50 of 0.8 nM for IL-8, 8.7 nM for IL-6 and 11.9 nM for TNF-α[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pharmacokinetic Analysis[1]
| Route | Dose (mg/kg) | T1/2 (h) | Tmax (h) | Cmax (ng·h/mL) | AUC (ng·h/mL) | Vd (L/kg) | Cl (mL/kg/min) | F (%) | |
| Mouse | iv | 2 | 1.2 | 2989 | 1.1 | 11.1 | |||
| po | 10 | 0.5 | 9610 | 19,236 | 129 | ||||
| Rat | iv | 2 | 1.7 | 7889 | 0.6 | 4.2 | |||
| po | 10 | 3.3 | 3323 | 18,803 | 48 | ||||
| Dog | iv | 1 | 2.1 | 1645 | 1.7 | 9.5 | |||
| po | 5 | 0.7 | 2192 | 10,800 | 131 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2772600-18-5
-
Appearance Solid
-
Masse moléculaire 383.40
-
Formule C19H18N3O2PS
-
Color Light yellow to yellow
-
SMILES
O=P(C)(C1=C(OC)C=C2N=CC=C(NC3=CC=C(SC=N4)C4=C3)C2=C1)C
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
DMSO : 5 mg/mL (13.04 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (276 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6082 mL | 13.0412 mL | 26.0824 mL | 65.2061 mL |
| 5 mM | 0.5216 mL | 2.6082 mL | 5.2165 mL | 13.0412 mL | |
| 10 mM | 0.2608 mL | 1.3041 mL | 2.6082 mL | 6.5206 mL |